You are viewing the site in preview mode

Skip to main content

Advertisement

Table 2 Hospitalizations during the 6-month follow up period

From: Hospitalization outcomes in patients with schizophrenia after switching to lurasidone or quetiapine: a US claims database analysis

Variable Medicaid population Commercial population
Lurasidone Quetiapine Lurasidone Quetiapine
n = 122 n = 215 n = 116 n = 220
Episodes (N)a 125 226 118 223
All-cause hospitalizations
 Episodes with ≥1 admission, (N, %) 19 15 52 23 12 10 44* 20
 Length of stay (first admission), (Mean, SD) 5.4 4.3 6.7* 4.8 10.9 14.5 9.3 8.8
 Cost, among episodes with an admission (Mean, SD) 15,448 13,741 22,012* 23,581 16,265 16,377 27,368* 46,415
Mental health-related hospitalizations
 Episodes with ≥1 admission, (N, %) 18 14 48 21 10 9 42* 19
 Length of stay (first admission), (Mean, SD) 5.6 4.4 6.8* 5.0 12.5 15.5 9.8* 8.8
 Cost, among episodes with an admission (Mean, SD) 15,388 13,609 22,272* 24,385 16,512 17,903 27,398* 46,476
Schizophrenia-related hospitalizations
 Episodes with ≥1 admission, (N, %) 16 13 36 16 8 7 26 12
 Length of stay (first admission), (Mean, SD) 5.6 4.7 7.6* 5.0 14.4 17.0 13.8 21.7
 Cost, among episodes with an admission (Mean, SD) 14,193 12,876 21,579* 24,034 17,863 19,745 18,514 17,249
  1. aMonotherapy treatment episodes were defined as patients having more than one lurasidone or quetiapine prescription without overlapping other antipsychotics during the post-index period. As some patients had multiple episodes, the N value in this row refers to the number of episodes in the sample that were evaluated
  2. *(p < .05); Statistically significantly different from lurasidone cohort